SkylineDx inks collaboration agreement with Imperial College London and UCSD on diagnostic test Kawasaki Disease
ROTTERDAM (the Netherlands), SAN DIEGO (US), LONDON (UK), September 10, 2020: SkylineDx, announces a collaboration agreement with Professor Michael Levin’s group at Imperial College London and Professor Jane Burns’ group at
read more
How the Dutch resume elective surgery in melanoma after COVID delays
ROTTERDAM (the Netherlands) and SAN DIEGO (US), August 26, 2020: SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to manage
read more
SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate both melanoma
read more
Prognostic model reveals high-risk melanoma patients that need a clinical trial
ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could benefit from
read more
Private health insurance reimburses MMprofiler with SKY92 for patients United Kingdom
ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with multiple myeloma (blood cancer) to
read more
SkylineDx launches melanoma test in United States to support cancer care
ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from their CAP/CLIA lab in San
read more
Skin cancer test reduces need for surgery
ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 15, 2020: SkylineDx in collaboration with the Mayo Clinic published yesterday its first study describing a diagnostic test that could reduce up to 42% of surgical interventions used to
read more
SkylineDx and BioInvent to collaborate on patient stratification to maximize impact of treatment with BI-1206
ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 24, 2020: SkylineDx today announces an agreement with BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients pre-
read more
National Research Cancer Institute UK confirms benefit molecular profiling in multiple myeloma
ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 17, 2020: multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide
read more
First German hospital to implement MMprofiler (SKY92) in real-world setting
ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 4, 2020: SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II
read more
SkylineDx confirms positive results first independent validation skin cancer test
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 30, 2019: SkylineDx announced, during the European Society for Medical Oncology congress (Barcelona, EU), that it successfully validated the performance of their skin cancer
read more
SkylineDx and Mayo Clinic collaborate on implementing skin cancer test in clinical practice
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 24, 2019: SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester (MN, US) the launch of a pilot study it will conduct with the
read more
Combination of multiple myeloma diagnostics finds lenalidomide benefit
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 12, 2019: fast-progressing multiple myeloma (blood cancer) patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with
read more
03 September 2019 FD release
Translation of Dutch newspaper (Het Financieele Dagblad) article written by Thieu Vaessen. Source can be found via this link. *** Van Herk puts € 20 million into diagnostics company for skin cancer The
read more
Dutch company receives EUR 20 million for skin cancer diagnostic test
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 2, 2019: Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing
read more
UK Commercialization Partner for Multiple Myeloma Diagnostics
ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 25th, 2019: hematologists and multiple myeloma (blood cancer) patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the
read more
Dutch Hospital First to Use Multiple Myeloma Diagnostic Test
ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 23rd, 2019: the academic hematology department of Erasmus Medical Center (EMC) is globally the first hospital to offer every multiple myeloma (blood cancer) patient an innovative
read more
Erasmus MC biedt als eerste test aan bij multipel myeloom
ROTTERDAM en SAN DIEGO (Verenigde Staten), 23 juli 2019: de hematologie afdeling van het Erasmus Medisch Centrum (EMC) is wereldwijd het eerste ziekenhuis dat elke multipel myeloom (bloedkanker) patiënt een innovatieve diagnostische
read more
Dutch scale-up SkylineDx secures respected CAP/CLIA certification for US laboratory
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 26th, 2019: the Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical Laboratory Improvement
read more
Study Results Show Significant Improvement Multiple Myeloma Care
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 13th, 2019: a substantial number of blood cancer (multiple myeloma) patients could make more informed decisions on their treatment if more information becomes available for them and their
read more
Studieresultaten Tonen Significante Verbetering Multipel Myeloom Zorg
ROTTERDAM en SAN DIEGO (Verenigde Staten), 13 juni 2019: een aanzienlijk aantal bloedkanker (multipel myeloom) patiënten kunnen beter beslissen over een behandeling als er meer informatie over hun diagnose beschikbaar komt voor hen en
read more
Dutch Multiple Myeloma Diagnostic Able To Guide Treatment
ROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk
read more
Dutch government grants €2.7M for development skin cancer test
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a
read more
Nederlandse overheid financiert € 2,7M voor ontwikkeling huidkankertest
ROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling van
read more
Groundbreaking algorithm predicts best treatment for cancer patient
ROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual cancer patients to
read more
Baanbrekend algoritme voorspelt beste behandeling kankerpatiënt
ROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een
read more
Machine learning algorithm predicts treatment response in MM
ROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives predictive
read more
SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma
SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the
read more
SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma
Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the
read more
SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler with SKY92 in Multiple Myeloma
First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial
read more
SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma
Poster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92 Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th
read more
SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial
ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today
read more
SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)
Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS) Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the
read more
SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival
Presentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx
read more
SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma
New Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the
read more
SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan
The Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 - SkylineDx is pleased to announce
read more
SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission
Project Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 - SkylineDx today announced
read more
SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)
Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 - SkylineDx today announced the
read more
SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease
ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 -- SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF) to
read more
SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting
Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD
read more
SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma
CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD
read more
SKY92-ISS Superior to current markers in risk classification for myeloma survival
Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at
read more
SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO
Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 - SkylineDx, a
read more
More Accurate Prediction on Prognosis in Multiple Myeloma (bone marrow cancer)
Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the
read more
SkylineDx Presents an Abstract on Risk Identification for Multiple Myeloma Patients at the 20th Congress of the EHA
Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple Myeloma (MM) patients and the clinical
read more